

# 1st Bart's International Mesothelioma Symposium

A one-day meeting focusing on the clinical and research aspects of malignant mesothelioma.

Organised by Bart's Mesothelioma Research  
[www.mesothelioma.co.uk](http://www.mesothelioma.co.uk)  
(Co-directors: Dr RM Rudd and Dr JPC Steele)

Guest speakers include:

Dr Hedy L. Kindler MD  
Assistant Professor of Medicine, University of Chicago Cancer Center

Prof Jan Van Meerbeeck MD PhD  
Head of Thoracic Oncology, Department of Respiratory Diseases,  
University Hospital and University of Ghent, Belgium

Registration fee: £50

CPD credits applied for through the Royal College of Physicians

30th September 2005 at The Great Hall, St Bartholomew's Hospital  
Sponsored by Field Fisher Waterhouse



# Programme

## 09.30 Registration and tea/coffee

## 09.45 Introduction



Robin M. Rudd MD FRCP  
Co-Director of Bart's Mesothelioma Research

Robin is Co-Director of Bart's Mesothelioma Research. He is a Consultant in Medical Oncology at St Bartholomew's Hospital. He trained in medicine at Cambridge University and St George's Hospital, London before undertaking research into industrial lung diseases at the Royal Brompton Hospital. Robin was a founder of the London Lung Cancer Group – one of Britain's most successful clinical research collaborative groups.

Robin is known around the world as an expert on the diagnosis and treatment of mesothelioma, lung cancer and other asbestos-related diseases.

## 10.00 Targeted Therapy for Mesothelioma

Hedy L. Kindler MD

Assistant Professor of Medicine, University of Chicago Cancer Center, Chicago, Illinois  
Chair, Mesothelioma Subcommittee, Cancer and Leukemia Group B

## 10.40 Apoptosis in Mesothelioma

Dean A. Fennell PhD MRCP

Cancer Research UK Clinician Scientist and Consultant  
Senior Lecturer in Medical Oncology at Queen's University, Belfast

## 11.05 Discussion

## 11.15 Tea/coffee

## 11.30 Imaging of Mesothelioma

James Entwisle MRCP FRCR

Consultant Radiologist, University of Leicester Hospitals

## 11.55 Controversies in the Pathological Diagnosis of Mesothelioma

Michael T. Sheaff FRCPath

Consultant Histopathologist, Bart's Mesothelioma Research, Bart's and The London NHS Trust

## 12.15 Research by Bart's Mesothelioma Research group

Astero Klabatsa MSc

Research Fellow, Bart's Mesothelioma Research

## 12.30 Discussion

# Programme

## 12.45 Lunch

## 13.45 Introduction



**Jeremy P.C. Steele MD MRCP**  
Co-Director, Barts Mesothelioma Research

Jeremy is Co-Director of Bart's Mesothelioma Research. He is a Consultant in Medical Oncology at St Bartholomew's Hospital, the Royal London Hospital and the London Chest Hospital. He qualified in medicine at St George's Hospital, London in 1989. After training in general medicine and intensive care, he moved to the Royal Marsden Hospital where he treated his first mesothelioma patient.

At the Institute of Cancer Research he undertook doctoral research into paediatric leukaemia and brain tumours. Jeremy moved to Bart's in 1997 where he has worked closely with Robin Rudd ever since and in 2000 he was awarded the Royal Society of Medicine Sylvia Lawler Prize. Jeremy is a member of the Board of Directors of the International Mesothelioma Interest Group and numerous other mesothelioma clinical and research groups in the UK and abroad. Jeremy is chairman of *Mesothelioma UK*.

## 14.00 Chemotherapy: Where are we now and what next?

Recent phase 3 results with new generation antifolates combined with cisplatin have resulted in a so-called standard chemotherapy regimen. However, several questions with regard to this standard remain open and will be discussed during this presentation.

**Prof Jan van Meerbeeck MD PhD**

Head of Thoracic Oncology, Department of Respiratory Diseases, University Hospital and University of Ghent, Belgium

## 14.35 Surgical Techniques in Mesothelioma

**Loic Lang-Lazdunski MD PhD FRCS**

Consultant Thoracic Surgeon, Guy's Hospital, London

## 15.00 Discussion

## 15.15 Tea/coffee

## 15.30 The MARS trial of radical surgery for mesothelioma

The present status of the MARS trial and its rationale, purpose and design will be presented.

**Tom Treasure MD MS FRCS (Guy's Hospital, London):**

Professor of Cardiothoracic Surgery London University and Consultant Thoracic Surgeon Guy's and St Thomas NHS Foundation Trust

## 15.55 Trial Design in Mesothelioma

**Richard Stevens PhD**

Senior Statistician, Medical Research Council, London

## 16.20 Discussion and closing remarks

## 16.30 Drinks

# How to book

- Please complete one registration form for each delegate.
- Cheques should be made payable to **Mesothelioma and Lung Cancer Research**.
- **Please send registration form with payment of £50 to Miss H Bains, Field Fisher Waterhouse, 35 Vine Street, London EC3N 2AA**. Confirmation will be sent to you in due course.
- For more details, please contact Miss H Bains (harminder.bains@ffw.com; 020 7861 4274).

Mr/Mrs/Ms/Miss/Dr/Other.....

Forename(s) .....

Surname .....

Position .....

Hospital/Company.....

Address .....

.....

.....

Tel.....

Fax.....

E-mail .....

[www.mesothelioma.co.uk](http://www.mesothelioma.co.uk)



**Venue address:** The Great Hall, St Bartholomew's Hospital, West Smithfield, London EC1A 7BE.

**Travel directions:** St Bartholomew's Hospital is near Smithfield Market, a few minutes walk from St Paul's Cathedral.

**British Rail:** Blackfriars, City Thameslink, Farringdon.

**Underground:** St Paul's (Central line), Farringdon and Barbican (Metropolitan and Circle lines), Blackfriars (District and Circle lines).

**Car Parking:** There is NCP parking in Smithfield Square and meters in the streets nearby.



A - this is the entrance to the Great Hall